SHARED RESOURCE MANAGEMENT ? ABSTRACT Shared Resources are organized and maintained to meet the scientific needs of the members of Karmanos Cancer Institute (KCI). KCI operates eight center-managed Shared Resources as follows; Animal Model and Therapeutics Evaluation Core (AMTEC), Biobanking and Correlative Sciences (BCS) Core, Behavioral and Field Research Core (BFRC), Biostatistics and Bioinformatics Core (BBC), Epidemiology Research Core (ERC), Microscopy, Imaging, and Cytometry Resources (MICR) Core, Pharmacology and Metabolomics Core (PMC), and a Proteomics Core. Together, these Shared Resources provide access to specialized technologies, services, and expertise that enhance scientific interaction and productivity at the Cancer Center. Of the 1,775 peer-reviewed articles published by cancer center members during the current reporting period (12/1/2015 ? 11/30/2019), 561 (31.6%) articles utilized the services of at least one KCI Shared Resource. KCI Shared Resources are managed within the planning and evaluation structure of the Cancer Center including senior leadership oversight of the scientific and strategic progress, reporting and business management provided by Administration, and regular user feedback provided through survey tools and Core Advisory Committees. Future plans are proposed to address the needs of the membership and the scientific progress of the Cancer Center. Additionally, a developing Cyclotron-Radiochemistry Core will provide various radiotracers for pre- clinical and clinical research conducted by the Cancer Center membership on a fee-for-service basis. CCSG funding for Cores was augmented by institutional support in excess of $6.0 million directed to ensure success of Shared Resources.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wayne State University
United States
Zip Code
Mitrea, Cristina; Wijesinghe, Priyanga; Dyson, Greg et al. (2018) Integrating 5hmC and gene expression data to infer regulatory mechanisms. Bioinformatics 34:1441-1447
Ma, Huiyan; Ursin, Giske; Xu, Xinxin et al. (2018) Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis. Breast Cancer Res 20:5
Luca, Francesca; Kupfer, Sonia S; Knights, Dan et al. (2018) Functional Genomics of Host-Microbiome Interactions in Humans. Trends Genet 34:30-40
Simon, Michael S; Beebe-Dimmer, Jennifer L; Hastert, Theresa A et al. (2018) Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. Cancer 124:1798-1807
Bock, Cathryn H; Jay, Allison M; Dyson, Gregory et al. (2018) The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Res Treat 167:741-749
Hastert, T A; de Oliveira Otto, M C; Lê-Scherban, F et al. (2018) Association of plasma phospholipid polyunsaturated and trans fatty acids with body mass index: results from the Multi-Ethnic Study of Atherosclerosis. Int J Obes (Lond) 42:433-440
Heyza, Joshua; Lei, Wen; Watza, Donovan et al. (2018) Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res :
Mittal, Sandeep; Klinger, Neil V; Michelhaugh, Sharon K et al. (2018) Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. J Neurosurg 128:414-421
Park, Hyo K; Schildkraut, Joellen M; Alberg, Anthony J et al. (2018) Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. Cancer Causes Control 29:1081-1091
Su, Yongwei; Li, Xinyu; Ma, Jun et al. (2018) Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol 148:13-26

Showing the most recent 10 out of 826 publications